相似文献
1
Campath-1H induced pure red cell aplasia in a patient with chronic lymphatic leukaemia.
Leuk Res. 2007 Jul;31(7):1025-6. doi: 10.1016/j.leukres.2006.08.012. Epub 2006 Sep 26.
2
Tuberculosis due to Mycobacterium bovis after alemtuzumab administration.
Clin Infect Dis. 2003 Jul 15;37(2):e27-8. doi: 10.1086/375690. Epub 2003 Jul 9.
3
Alemtuzumab for B-cell chronic lymphocytic leukemia.
Expert Rev Anticancer Ther. 2008 Jul;8(7):1033-51. doi: 10.1586/14737140.8.7.1033.
4
[Persistent influenza virus infection in a patient treated with alemtuzumab].
Med Mal Infect. 2010 Nov;40(11):657-9. doi: 10.1016/j.medmal.2010.03.001. Epub 2010 Jul 16.
5
Campath-1H for chronic lymphocytic leukemia.
Clin Lymphoma. 2002 Sep;3(2):73-4. doi: 10.3816/clm.2002.n.013.
6
Treatment of pure red cell aplasia and autoimmune haemolytic anaemia in chronic lymphocytic leukaemia with Campath-1H.
Eur J Haematol. 2003 May;70(5):319-21. doi: 10.1034/j.1600-0609.2003.00055.x.
7
[A new therapeutic alternative in chronic B-lymphocytic leukemia].
Rev Infirm. 2002 Dec(86):38-40.
8
Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative disorders with the anti-CD52 monoclonal antibody alemtuzumab (Campath-1H).
Br J Haematol. 2003 Oct;123(2):278-81. doi: 10.1046/j.1365-2141.2003.04609.x.
9
Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy.
N Engl J Med. 2002 Aug 8;347(6):452-3. doi: 10.1056/NEJM200208083470619.
10
Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation.
Leukemia. 2006 Dec;20(12):2204-7. doi: 10.1038/sj.leu.2404435. Epub 2006 Oct 19.
Zotero 插件